Aurinia Pharma to buy Kezar Life Sciences for $6.955 a share plus CVR

Reuters04-04

Aurinia Pharma to buy <a href="https://laohu8.com/S/KZR">Kezar Life</a> Sciences for $6.955 a share plus CVR

Aurinia Pharmaceuticals agreed to acquire Kezar Life Sciences for USD 6.955 per share in cash plus a non-transferable contingent value right.
CVR provides potential payouts tied to development or disposition of Kezar lead asset zetomipzomib, selected collaboration and asset-sale proceeds, and net cash above USD 50 million at closing.
Aurinia plans to launch a tender offer by April 13, 2026, for all outstanding Kezar shares.
Closing is expected in Q2 2026, subject to a majority of shares tendered and Kezar meeting a net-cash condition above USD 50 million.
Tang Capital Partners, holding about 9.0% of Kezar shares, signed a tender and support agreement backing transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001600620-26-000035), on April 03, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624664225?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-04 04:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624664225","market":"nz","top_or_hot":-1,"title":"Aurinia Pharma to buy Kezar Life Sciences for $6.955 a share plus CVR","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aurinia Pharma to buy <a href=\"https://laohu8.com/S/KZR\">Kezar Life</a> Sciences for $6.955 a share plus CVR\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Aurinia Pharmaceuticals agreed to acquire Kezar Life Sciences for USD 6.955 per share in cash plus a non-transferable contingent value right.\n        </li>\n<li>\n          CVR provides potential payouts tied to development or disposition of Kezar lead asset zetomipzomib, selected collaboration and asset-sale proceeds, and net cash above USD 50 million at closing.\n        </li>\n<li>\n          Aurinia plans to launch a tender offer by April 13, 2026, for all outstanding Kezar shares.\n        </li>\n<li>\n          Closing is expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, subject to a majority of shares tendered and Kezar meeting a net-cash condition above USD 50 million.\n        </li>\n<li>\n          Tang Capital Partners, holding about 9.0% of Kezar shares, signed a tender and support agreement backing transaction.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a>. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001600620-26-000035), on April 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aurinia Pharma to buy Kezar Life Sciences for $6.955 a share plus CVR</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAurinia Pharma to buy Kezar Life Sciences for $6.955 a share plus CVR\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-04 04:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aurinia Pharma to buy <a href=\"https://laohu8.com/S/KZR\">Kezar Life</a> Sciences for $6.955 a share plus CVR\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Aurinia Pharmaceuticals agreed to acquire Kezar Life Sciences for USD 6.955 per share in cash plus a non-transferable contingent value right.\n        </li>\n<li>\n          CVR provides potential payouts tied to development or disposition of Kezar lead asset zetomipzomib, selected collaboration and asset-sale proceeds, and net cash above USD 50 million at closing.\n        </li>\n<li>\n          Aurinia plans to launch a tender offer by April 13, 2026, for all outstanding Kezar shares.\n        </li>\n<li>\n          Closing is expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, subject to a majority of shares tendered and Kezar meeting a net-cash condition above USD 50 million.\n        </li>\n<li>\n          Tang Capital Partners, holding about 9.0% of Kezar shares, signed a tender and support agreement backing transaction.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a>. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001600620-26-000035), on April 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KZR","symbol_name":"Kezar Life Sciences Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL9hGLjS:1","article_id":"2624664225","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624664225","pubTimestamp":1775249915,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aurinia Pharmaceuticals agreed to acquire Kezar Life Sciences for USD 6.955 per share in cash plus a non-transferable contingent value right.CVR provides potential payouts tied to development or disposition of Kezar lead asset zetomipzomib, selected collaboration and asset-sale proceeds, and net cash above USD 50 million at closing.Aurinia plans to launch a tender offer by April 13, 2026, for all outstanding Kezar shares.Closing is expected in Q2 2026, subject to a majority of shares tendered and Kezar meeting a net-cash condition above USD 50 million.Tang Capital Partners, holding about 9.0% of Kezar shares, signed a tender and support agreement backing transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceutical","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KZR":"Kezar Life Sciences Inc.","BK4139":"生物科技","AUPH":"Aurinia Pharmaceuticals Inc"},"translate_title":"Aurinia Pharma将以每股6.955美元加CVR收购Kezar Life Sciences","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KZR":0.9,"AUPH":0.9},"content_text":"Aurinia Pharma to buy Kezar Life Sciences for $6.955 a share plus CVR\n    \n\n\n          Aurinia Pharmaceuticals agreed to acquire Kezar Life Sciences for USD 6.955 per share in cash plus a non-transferable contingent value right.\n        \n\n          CVR provides potential payouts tied to development or disposition of Kezar lead asset zetomipzomib, selected collaboration and asset-sale proceeds, and net cash above USD 50 million at closing.\n        \n\n          Aurinia plans to launch a tender offer by April 13, 2026, for all outstanding Kezar shares.\n        \n\n          Closing is expected in Q2 2026, subject to a majority of shares tendered and Kezar meeting a net-cash condition above USD 50 million.\n        \n\n          Tang Capital Partners, holding about 9.0% of Kezar shares, signed a tender and support agreement backing transaction.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001600620-26-000035), on April 03, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624664225","isCrawlerRequest":true}